F8 and hemophilia B: Third, for protein-based therapy, development of neutralizing antibodies (called inhibitors) occurs much more frequently against FVIII (7–52%) than FIX (1–3%) [8], thus favoring hemophilia B for experimental treatments such as gene therapy.